Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”), has awarded the company $590 million to accelerate the development of an mRNA-based vaccine program aimed at preventing the spread of the H5N1 virus,
$590m to Moderna from HHS for mRNA ‘flu vax development
"$590m to Moderna from HHS for mRNA ‘flu vax development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Moderna confirms $590M award by U.S. for bird flu vaccine development
Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Moderna Gets $590 Million to Develop Bird Flu Vaccine
The government is working to head off human bird flu infections. The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
UMass Lowell1y
Biomedical Advanced Research and Development Authority (BARDA)
Specifically, BARDA supports the advanced development and procurement of drugs, vaccines, and other products that are considered priorities for responding to and recovering from threats to ...
Emergent BioSolutions stock reaffirms buy rating on contract modification
H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...
Business Wire8d
Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a C ...
The Bakersfield Californian8d
Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to ...
Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, ...
Emergent BioSolutions receives contract option valued at $16.7M
Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority executed a contract modification for the ...
GovCon Wire1d
Alliance for Advancing Biomedical Research Secures $89B NIH FFRDC Operation Contract
Learn more about a recompete NIH contract awarded to the Alliance for Advancing Biomedical Research to operate NCI's ...
Yahoo Finance25d
Vaxart project agreement change ups funding for oral COVID vaccine candidate
the Consortium Management Firm of the Rapid Response Partnership Vehicle funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services.
The Bakersfield Californian9d
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to ...
This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 millionProgram progress and performance ...